JP2002538170A - 喘息の治療における抗−ＴＮＦα抗体 - Google Patents

喘息の治療における抗−ＴＮＦα抗体

Info

Publication number
JP2002538170A
JP2002538170A JP2000602303A JP2000602303A JP2002538170A JP 2002538170 A JP2002538170 A JP 2002538170A JP 2000602303 A JP2000602303 A JP 2000602303A JP 2000602303 A JP2000602303 A JP 2000602303A JP 2002538170 A JP2002538170 A JP 2002538170A
Authority
JP
Japan
Prior art keywords
antibody
tnfα
antigen
antibodies
asthma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000602303A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002538170A5 (https=
Inventor
トレーシー，ジョージ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of JP2002538170A publication Critical patent/JP2002538170A/ja
Publication of JP2002538170A5 publication Critical patent/JP2002538170A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2000602303A 1999-03-02 2000-03-01 喘息の治療における抗−ＴＮＦα抗体 Pending JP2002538170A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26095399A 1999-03-02 1999-03-02
US09/260,953 1999-03-02
US46569199A 1999-12-17 1999-12-17
US09/465,691 1999-12-17
PCT/US2000/005163 WO2000051637A1 (en) 1999-03-02 2000-03-01 ANTI-TNFα ANTIBODIES IN THERAPY OF ASTHMA

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010195818A Division JP2011006464A (ja) 1999-03-02 2010-09-01 喘息の治療における抗−ＴＮＦα抗体

Publications (2)

Publication Number Publication Date
JP2002538170A true JP2002538170A (ja) 2002-11-12
JP2002538170A5 JP2002538170A5 (https=) 2010-10-28

Family

ID=26948290

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000602303A Pending JP2002538170A (ja) 1999-03-02 2000-03-01 喘息の治療における抗−ＴＮＦα抗体
JP2010195818A Pending JP2011006464A (ja) 1999-03-02 2010-09-01 喘息の治療における抗−ＴＮＦα抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010195818A Pending JP2011006464A (ja) 1999-03-02 2010-09-01 喘息の治療における抗−ＴＮＦα抗体

Country Status (10)

Country Link
US (3) US20010021381A1 (https=)
EP (1) EP1159003B1 (https=)
JP (2) JP2002538170A (https=)
AT (1) ATE488250T1 (https=)
AU (1) AU756677B2 (https=)
CA (1) CA2364026C (https=)
DE (1) DE60045240D1 (https=)
DK (1) DK1159003T3 (https=)
PT (1) PT1159003E (https=)
WO (1) WO2000051637A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517214A (ja) * 2003-02-11 2006-07-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規な抗コリン作用剤とＴＮＦα合成又は作用阻害剤に基づく新規な医薬組成物
JP2010533181A (ja) * 2007-07-13 2010-10-21 アボツト・バイオテクノロジー・リミテツド ＴＮＦα阻害剤の肺投与のための方法及び組成物
JP2014508930A (ja) * 2011-02-17 2014-04-10 ネステク ソシエテ アノニム 抗ＴＮＦα薬に対する自己抗体を検出するためのアッセイ

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2341952A1 (en) * 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
KR20090078349A (ko) 2006-10-12 2009-07-17 제넨테크, 인크. 림포톡신-알파에 대한 항체
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
MX2010012473A (es) 2008-05-23 2011-02-23 Siwa Corp Metodos, composiciones y aparato para facilitar la regeneracion.
CN107001459B (zh) 2014-09-19 2021-11-23 Siwa有限公司 用于治疗炎症和自身免疫紊乱的抗age抗体
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
PT3337829T (pt) 2016-02-19 2020-02-10 Siwa Corp Método e composição para o tratamento do cancro, matando células cancerosas metastáticas e prevenindo as metástases do cancro usando anticorpos para produtos finais de glicação avançada (pga)
CA3057829A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
WO2017222535A1 (en) 2016-06-23 2017-12-28 Siwa Corporation Vaccines for use in treating various diseases and disorders
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
CN115804821B (zh) * 2022-12-19 2024-05-14 新疆维吾尔药业有限责任公司 寒喘祖帕颗粒在制备治疗激素抵抗型哮喘药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029131A1 (en) * 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
WO1998051344A1 (en) * 1997-05-12 1998-11-19 The Kennedy Institute Of Rheumatology Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822776A (en) * 1981-09-08 1989-04-18 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US6419927B1 (en) * 1981-09-08 2002-07-16 Anthony Cerami Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages
US6309640B1 (en) * 1981-09-08 2001-10-30 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4603106A (en) * 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
EP0288088B1 (en) * 1987-04-24 1994-03-09 Teijin Limited Detection of tumor necrosis factor; monoclonal antibody and kit
US5360716A (en) * 1988-10-24 1994-11-01 Otsuka Pharmaceutical Co., Ltd. Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α
US5223395A (en) * 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
GB8921123D0 (en) * 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
AU8910891A (en) * 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
EP1097945B1 (en) * 1991-03-18 2007-07-04 New York University Monoclonal and chimeric antibody specific for human tumor necrosis factor
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
DE4139733A1 (de) * 1991-11-28 1993-06-03 Schering Ag Carbacyclinderivate als mittel zur behandlung von krankheitsbildern, die zum atopie-kreis gehoeren
AU5152293A (en) * 1992-10-08 1994-05-09 Kennedy Institute Of Rheumatology, The Treatment of autoimmune and inflammatory disorders
EP0671936A1 (en) * 1992-10-15 1995-09-20 Dana-Farber Cancer Institute, Inc. TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-$g(a) FUNCTION
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
US20050260201A1 (en) * 1993-01-29 2005-11-24 Centocor, Inc. Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins
ES2159529T5 (es) * 1993-03-05 2011-03-09 Bayer Corporation Anticuerpos monoclonales humanos anti-tnf alfa.
SE9302490D0 (sv) * 1993-07-26 1993-07-26 Kabi Pharmacia Ab New use of old drugs
GB9403909D0 (en) * 1994-03-01 1994-04-20 Erba Carlo Spa Ureido derivatives of naphthalenephosphonic acids and process for their preparation
GB9702088D0 (en) * 1997-01-31 1997-03-19 Pharmacia & Upjohn Spa Matrix metalloproteinase inhibitors
TR199902562T2 (xx) * 1997-04-15 2000-02-21 Farmaceutisk Laboratorium Ferring A/S De�i�tirilmi� TNF alfa molek�lleri

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029131A1 (en) * 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
WO1998051344A1 (en) * 1997-05-12 1998-11-19 The Kennedy Institute Of Rheumatology Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517214A (ja) * 2003-02-11 2006-07-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規な抗コリン作用剤とＴＮＦα合成又は作用阻害剤に基づく新規な医薬組成物
JP2010533181A (ja) * 2007-07-13 2010-10-21 アボツト・バイオテクノロジー・リミテツド ＴＮＦα阻害剤の肺投与のための方法及び組成物
JP2014062095A (ja) * 2007-07-13 2014-04-10 Abbvie Biotechnology Ltd ＴＮＦα阻害剤の肺投与のための方法及び組成物
JP2014508930A (ja) * 2011-02-17 2014-04-10 ネステク ソシエテ アノニム 抗ＴＮＦα薬に対する自己抗体を検出するためのアッセイ

Also Published As

Publication number Publication date
US20010021381A1 (en) 2001-09-13
JP2011006464A (ja) 2011-01-13
US20060222646A1 (en) 2006-10-05
ATE488250T1 (de) 2010-12-15
CA2364026A1 (en) 2000-09-08
DK1159003T3 (da) 2011-02-07
WO2000051637A1 (en) 2000-09-08
CA2364026C (en) 2012-08-21
EP1159003B1 (en) 2010-11-17
US20020119152A1 (en) 2002-08-29
AU756677B2 (en) 2003-01-23
AU3386100A (en) 2000-09-21
DE60045240D1 (de) 2010-12-30
PT1159003E (pt) 2011-02-22
EP1159003A1 (en) 2001-12-05

Similar Documents

Publication Publication Date Title
JP2011006464A (ja) 喘息の治療における抗−ＴＮＦα抗体
JP5137983B2 (ja) 補体成分ｃ５に対する抗体を使用する喘息の処置の方法
JP5177444B2 (ja) Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
JP4954104B2 (ja) Ｉｌ−５介在障害を治療および診断するための改良方法
JP4970258B2 (ja) ヒトインターロイキン−１３に対する抗体およびそれらの使用
JP5366930B2 (ja) Ｉｌ−２５に対する抗体
US20090017020A1 (en) Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
JP2008029355A (ja) Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
CN104755495A (zh) 通过施用il-4r拮抗剂治疗或预防哮喘的方法
CN101133084A (zh) 采用白细胞介素-1ⅰ型受体拮抗剂治疗呼吸道疾病的方法
JPH11510172A (ja) アレルギー性喘息の治療法
CN103857411A (zh) 使用抗il-13抗体治疗哮喘的方法和组合物
JP7458790B2 (ja) Ｉｌ－６阻害剤を含有する喘息の治療剤
TW202320847A (zh) 一種抗ａｎｇｐｔｌ３抗體或其抗原結合片段的醫藥組成物及其用途
CN112839961B (zh) 一种cd40抗体药物组合物及其用途
ES2357749T3 (es) Anticuerpos anti-tnf alfa en la terapia del asma resistente a esteroides.
CN101022828A (zh) B因子、补体旁路的抑制及与此相关的方法
RU2801531C2 (ru) Способы лечения или предотвращения астмы посредством введения антагониста il-4r
JP2002501905A (ja) ＩｇＥアンタゴニストによるアトピー性皮膚炎の治療
JP2026503045A (ja) Ｔｓｌｐ抗体を使用して喘息を治療するための方法
CN121889429A (zh) 用于治疗嗜酸性肉芽肿性多血管炎的IL-5R-α抗体
HK40078655A (en) Pharmaceutical composition containing anti-il-4r antibody and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070228

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20071001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20071001

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20071001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100601

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100608

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110311

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20110715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111004

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120228